Solid Biosciences Inc. (SLDB) vs Starling Oncology, Inc. (STLN)

A side-by-side comparison of Solid Biosciences Inc. and Starling Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

SLDB

Solid Biosciences Inc.

$681M

$6.92HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

STLN

Starling Oncology, Inc.

$658M

$6.58HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — SLDB vs STLN

growth of $100 · dividends reinvested · last 1y

SLDB -34.9% (-34.9%/yr)STLN +8.6% (+8.6%/yr)STLN compounded faster over this window

SLDB STLN

SLDB vs STLN: by the numbers

•SLDB is the larger company ($681M vs $658M market cap).
•Both run net losses; SLDB's is the smaller (0.00% vs -6.18% net margin).

Metrics side by side

Valuation

Metric	SLDB	STLN
P/S ratio	N/A	1.12
P/B ratio	1.82	N/A

Profitability

Metric	SLDB	STLN
Gross margin	0.00%	15.69%
Operating margin	0.00%	-4.44%
Net margin	0.00%	-6.18%
ROE	-55.36%	N/A
ROIC	-54.12%	-31.32%

Growth (annualized)

Metric	SLDB	STLN
Total return CAGR (5Y)	-27.50%	N/A

Go deeper

Full SLDB analysis Full STLN analysis Interactive comparison tool

Dig into the metrics

Solid Biosciences ROE Starling Oncology ROE Solid Biosciences operating margin Starling Oncology operating margin Solid Biosciences revenue growth Starling Oncology revenue growth Solid Biosciences free cash flow Starling Oncology free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.